Public Health

With nearly all states poised to allow anyone at least 16 years old to get a COVID-19 vaccine, this week’s announcement pausing the distribution of the Johnson & Johnson vaccine to investigate a rare side effect is raising questions about whether and how it will affect the public’s eagerness to…

With supply having increased significantly and eligibility fully open to adults in all states as of April 19, this analysis estimates that COVID-19 vaccine supply will exceed demand across the U.S. over the next 2 to 4 weeks.

In the course of the pandemic, health officers have become the face of local government authority. And, in turn, many have become targets for the rage and resentment of some of the same loose-knit militia and white nationalist groups that stormed the U.S. Capitol in January, smashing windows, bloodying officers…

This issue brief examines key issues related to multi-dose vaccination series generally as well as issues specific to COVID-19.

This report summarizes the public’s response to a series of open-ended questions aimed at better understanding people’s concerns around receiving a COVID-19 vaccine and the views of the messages and messengers that could affect their willingness to get one,

As the country broadens COVID-19 vaccine distribution efforts, the latest research from the KFF COVID-19 Vaccine Monitor finds that side effects, including allergic reactions and long-term consequences, are the public’s top concern about getting vaccinated when asked to describe what worries them in their own words. The latest report from…

Thirty-one percent of the public wants to “wait and see” how the COVID-19 vaccine is working for other people before getting vaccinated themselves. While they share a similar level of vaccine hesitancy, this group is not monolithic in their attitudes and beliefs. This brief examines how people with different partisan identities and those belonging to different racial and ethnic groups differ in their levels of concern about the vaccine and may respond differently to messages and information.

Nearly a third (31%) of the public says they want to “wait and see” how a COVID-19 vaccine works for others before they would get it, representing a critical group for efforts aimed at boosting vaccinations. The latest analysis from the KFF COVID-19 Vaccine Monitor highlights how attitudes differ by…

This Policy Watch examines how the 50 states and DC are defining “high-risk medical conditions” for COVID-19 vaccine prioritization, including whether they follow CDC’s recommendations or deviate in some way.

This policy watch looks at the expected ramp up in vaccine supply, and what this could mean for increasing the number of people getting vaccinated.